Legumain-Cleavable TOP1i ADC
Cancer
Pre-clinicalActive
Key Facts
About Manhattan Biosolutions
Manhattan BioSolutions is a private, preclinical-stage biotech focused on developing a novel platform for next-generation antibody-drug conjugates (ADCs). The company leverages expertise in antibody engineering, linker chemistry, and payload design to create ADCs that aim to overcome key limitations of current therapies, such as toxicity and resistance. It has built a robust network of academic and institutional collaborations, secured significant non-dilutive grant funding, and is advancing a pipeline of ADC candidates targeting various cancers.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |